Akt kinase plays a central role in cell growth, metabolism, and tumorigenesis. The TRAF6 E3 ligase orchestrates IGF-1-mediated Akt ubiquitination and activation. Here, we show that Akt ubiquitination is also induced by activation of ErbB receptors; unexpectedly, and in contrast to IGF-1 induced activation, the Skp2 SCF complex, not TRAF6, is a critical E3 ligase for ErbB-receptor-mediated Akt ubiquitination and membrane recruitment in response to EGF. Skp2 deficiency impairs Akt activation, Glut1 expression, glucose uptake and glycolysis, and breast cancer progression in various tumor models. Moreover, Skp2 overexpression correlates with Akt activation and breast cancer metastasis and serves as a marker for poor prognosis in Her2-positive patients. Finally, Skp2 silencing sensitizes Her2-overexpressing tumors to Herceptin treatment. Our study suggests that distinct E3 ligases are utilized by diverse growth factors for Akt activation and that targeting glycolysis sensitizes Her2-positive tumors to Herceptin treatment.
INTRODUCTION
Akt kinase is a key factor that conveys growth factor signals from outside the cell to inside the cell. It serves as a central node for the regulation of cell proliferation, cell survival, metabolism, and tumorigenesis (Brazil et al., 2002; Liu et al., 2009; Manning and Cantley, 2007; Yang et al., 2010a) . The recruitment of Akt kinase to the plasma membrane is a critical step for Akt phosphorylation and activation by growth-factor stimuli. Although the PIP3 formation-induced by PI3K activation is essential for Akt membrane recruitment, our recent study reveals that K63-linked ubiquitination of Akt is also required for this process. TRAF6 is found to be an ubiquitin ligase (E3) for Akt and plays a crucial role in Akt ubiquitination, membrane translocation, and phosphorylation upon stimulation with insulin-like growth factor-1 (IGF-1) (Yang et al., , 2010b . Thus, Akt ubiquitination and PIP3 binding are two important events required for Akt membrane recruitment and activation in response to IGF-1. However, it remains largely unclear whether Akt ubiquitination is universally engaged in Akt membrane translocation and activation triggered by other growth factor receptors, such as ErbB family.
Under normoxic condition, differentiated cells primarily utilize mitochondria oxidative phosphorylation to generate adenosine 5 0 -triphosphate (ATP) for biogenesis and cellular processes (Aragoné s et al., 2009; Vander Heiden et al., 2009 ). However, under hypoxia these cells switch their metabolism from aerobic oxidative phosphorylation to anaerobic glycolysis. Notably, tumor cells utilize aerobic glycolysis regardless of the oxygen levels, known as the Warburg effect. The elevated aerobic glycolysis seen in tumor cells rapidly generates ATP in order to meet their increased need for energy and biosynthesis to sustain tumor growth (Birnbaum, 2004; Plas and Thompson, 2005; Robey and Hay, 2009 ). Akt kinase is frequently activated in various tumor types and represents one of the main drivers for the Warburg effect (Elstrom et al., 2004) . Akt increases glucose uptake by enhancing transcription and membrane translocation of glucose transporters. It promotes glycolytic flux through increasing hexokinase and phosphofructokinase activity (Robey and Hay, 2009 ). Accumulating evidence shows that the activation of the Akt pathway causes increased dependency on aerobic glycolysis (Elstrom et al., 2004; Wieman et al., 2007) , suggesting that therapeutic strategies that target the Akt pathway can block glucose metabolism and consequently result in tumor regression. Although numerous downstream players involved in Akt-mediated glycolysis have been proposed, current knowledge regarding the upstream regulators of Aktdependent glycolytic pathway remains limited.
In this study, we unexpectedly discover that Skp2, rather than TRAF6, is critically involved in ErbB family-induced Akt ubiquitination, aerobic glycolysis and tumorigenesis. Importantly, targeting glycolysis by Skp2 deficiency sensitizes Her2-positive tumors to Herceptin treatment, highlighting the clinical value of Skp2 targeting in breast cancer therapy.
RESULTS

Skp2 Is Responsible for EGF-Mediated Akt Ubiquitination
To determine whether Akt ubiquitination is a common event induced by growth factors, we examined whether Akt ubiquitination is induced by activation of epidermal growth factor (EGF) receptor, a member of the ErbB receptor family. Indeed, in vivo ubiquitination assay revealed that endogenous Akt ubiquitination is also induced upon EGF treatment (Figures 1A and 1E ; Figure S1F , top, available online), suggesting that Akt ubiquitination is a general event triggered by growth factors. As TRAF6 is important for IGF-1-mediated Akt ubiquitination and activation , we determined whether EGF-mediated Akt ubiquitination and activation depend on TRAF6. To our surprise, EGF-induced ubiquitination of Akt and phosphorylation of Akt and Foxo1 were comparable between WT and Traf6 À/À MEFs (Figures S1A and S1B), suggesting that TRAF6 is dispensable for EGF-induced Akt activation. Skp2 is an F-Box protein that forms a Skp2 SCF complex with Skp1, Cullin-1 (Cul-1), and RBx1 to constitute an E3 ligase activity that triggers protein ubiquitination and degradation (Chan et al., 2010b; Nakayama and Nakayama, 2006) . Skp2 displays oncogenic activities by regulating cell cycle progression, senescence, and metastasis (Chan et al., 2010a (Chan et al., , 2011 Lin et al., 2009 Lin et al., , 2010 . As we have previously demonstrated that Akt physically interacts with Skp2 in vivo in response to IGF-1 , we determined whether Skp2 is engaged in EGF-mediated Akt ubiquitination. Although Akt ubiquitination upon EGF stimulation was induced in WT MEFs or controlknockdown cells, it was impaired in Skp2 À/À MEFs and Skp2 knockdown cells (Figures 1A and 1E and S1F, top) , indicating that Skp2 is required for EGF-induced Akt ubiquitination. Moreover, the interaction between endogenous Skp2 and Akt was also enhanced by EGF ( Figures 1B and S1C ), which occurred both in cytosol and nucleus ( Figure S1D ). Notably, Skp2 overexpression induced Akt ubiquitination in the absence of proteosome inhibitor, which did not cause Akt degradation ( Figure 1C ). Skp2 overexpression promoted lysine (K) 63-linked, rather than K48-linked, ubiquitination of Akt ( Figure 1D ). We further demonstrated that EGF markedly promoted endogenous K63-linked, rather than K48-linked, ubiquitination of Akt, which was diminished upon Skp2 deficiency ( Figures 1E, S1E , and S1F). Although TRAF6 knockdown reduced the basal Akt ubiquitination and IGF-1-induced Akt phosphorylation and activation, Skp2 overexpression was still able to efficiently induce Akt ubiquitination ( Figure S1G ), suggesting that Skp2 promotes Akt ubiquitination independent of TRAF6.
Diverse Growth Factors Utilize Distinct E3 Ligase for Akt Ubiquitination and Activation Although TRAF6 plays a critical role in IGF-1-mediated Akt ubiquitination and activation ), this current study shows that EGF selectively utilizes the Skp2 SCF complex to ubiquitinate Akt. To gain further mechanistic insights into how ErbB and IGF-1 selectivity utilize distinct E3 ligases for Akt activation, we investigated the possibility that EGF and IGF-1 may do so by regulating their E3 ligase activities. Skp2, but not TRAF6, interacted with EGFR and its E3 ligase activity was enhanced upon EGF treatment, as judged by the formation of the Skp2 SCF complex ( Figures 1F and S2A ). In contrast, TRAF6 associated with IGF-1Rb and its E3 ligase activity, as determined by TRAF6 auto-ubiquitination, was induced by IGF-1, but not by EGF stimulation ( Figures 1G and S2B ). Moreover, although IGF-1 readily activated TRAF6 within 15 min, it could not promote the formation of Skp2-SCF complex at this early time point, although it indeed does so after 1 hr (Figure S2C) , consistent with our previous observation . Additionally, the endogenous expression of Skp2 was not affected by IGF-1 stimulation within 1 hr ( Figure S2D) . Thus, these results demonstrated that Skp2 is not activated at early time points, but it is activated at longer time points. Because IGF-1 induces the association of TRAF6 with Akt ) and EGF stimulates the interaction between Skp2 and Akt (Figures 1B and S1C), we postulated that a potential mechanism responsible for this distinctive dependence on TRAF6 and Skp2 may be due to their different binding affinity for Akt. Indeed, we found that EGF selectively induced the interaction of Akt with Skp2, but not with TRAF6 ( Figure S2E ), providing an explanation of why Skp2, but not TRAF6, is involved in ErbB family-induced Akt ubiquitination. Given that phosphorylation is a well-characterized posttranslational modification that regulates protein-protein interaction, we hypothesized that IGF-1 and EGF may regulate the interaction of Akt with Skp2 or TRAF6 by inducing their phosphorylation. In support of this notion, TRAF6 was tyrosine-, but not serine/ threonine-, phosphorylated upon IGF-1 treatment ( Figure S2F , upper and middle panels). In contrast, EGF failed to induce TRAF6 tyrosine phosphorylation ( Figure S2F , lower panel). To further understand whether IGF-1-mediated TRAF6 phosphorylation may regulate TRAF6 and Akt interaction, we treated the TRAF6 immunocomplex with phosphatase to induce TRAF6 dephosphorylation and found that IGF-1-induced TRAF6 and Akt interaction was diminished ( Figure S2G ). Although Skp2 underwent tyrosine and serine/threonine phosphorylation upon EGF stimulation, the phosphatase treatment resulted in Skp2 dephosphorylation, accompanied by Skp2 and Akt dissociation (Figures S2H and S2I defects in Skp2 SCF E3 ligase activity (Chan et al., 2010a; Kim et al., 2003; Lin et al., 2009) , compromised this effect ( Figure 1H ). Of note, the impairment of Skp2-NES mutant in promoting Akt ubiquitination was not due to its defect in Akt binding (Figure S2J) . Likewise, Skp2-mediatd in vivo Akt ubiquitination was profoundly compromised upon Cul-1 or Skp1 knockdown (Figures 2A and 2B ). Interestingly, silencing both UbcH5c and Ubc13, two ubiquitin-conjugating enzymes (E2s) critical for K63-linked ubiquitination (Xia et al., 2009; Zeng et al., 2010) , attenuated Skp2-mediated Akt ubiquitination ( Figure 2C ). We found that Skp2, but not Skp1 and Cul-1, could directly interact with Akt ( Figure S3 ) and that Skp2 SCF complex readily triggered in vitro Akt ubiquitination, in a manner similar to that of TRAF6 ( Figure 2D ). Thus, Skp2 SCF complex is a direct E3 ligase for Akt. We next determined whether Skp2 SCF complex is required for EGF-mediated Akt activation. Strikingly, EGF-induced phosphorylation of Akt and Foxo1 were markedly reduced in Skp2
MEFs compared to that in WT MEFs ( Figure 3A ). We observed a similar impairment in EGF-mediated Akt phosphorylation upon Skp2, Cul-1, Skp1, UbcH5c, or Ubc13 knockdown ( Figures  3B and S4A-S4C ). Accordingly, these results indicate that the Skp2 SCF complex is critical for EGF-triggered Akt phosphorylation and activation. To determine whether Skp2 is also involved in Akt signaling activation by other ErbB family proteins, BT-474 breast cancer cells were treated with Heregulin (HRG), which is known to activate ErbB2 and ErbB3 (Agus et al., 2002; Lee-Hoeflich et al., 2008) . Notably, Skp2 knockdown also impaired Akt phosphorylation and activation in BT-474 cells upon HRG treatment ( Figure 3C ). These results suggest that Skp2 is generally involved in Akt activation in response to ErbB receptor signaling.
We next examined whether Skp2 regulates the ubiquitination of other Akt isoforms. Notably, we found ubiquitination of both Akt1 and Akt2, but not Akt3 were induced by Skp2 overexpression, although basal ubiquitination of Akt2 was lower than that of Akt1 ( Figure S4D ). Furthermore, Skp2 deficiency attenuated EGF-mediated Akt1 and Akt2 phosphorylation ( Figure S4E ), indicating that Skp2 is required for EGF-promoted activation of both Akt1 and Akt2.
As TRAF6-mediated Akt ubiquitination at K8 and K14 residues is critical for its membrane recruitment and activation (Yang Figure S4G . See also Figure S4 .
et al., 2009), we then validated whether these two sites are also being utilized by Skp2 SCF complex. Indeed, we found that K8 and K14 residues are essential sites for Skp2-mediated Akt ubiquitination ( Figure S4F ). Biochemical fractionation assay and immunofluorescence assay revealed that EGF-induced Akt membrane recruitment was dramatically impaired in Skp2
MEFs compared to that in WT MEFs (Figures 3D and 3E and S4G) . Although the binding of Akt to PIP3 is an essential step for Akt membrane recruitment and activation, our recent report reveals that K63-linked ubiquitination of Akt plays a dispensable role in Akt and PIP3 binding . We further excluded the possibility that Skp2 regulates Akt membrane recruitment and activation by affecting Akt and PIP3 binding ( Figure S4H ). Although Akt dimerization is also proposed to be important for Akt activation (Datta et al., 1995; Kü nstle et al., 2002; Noguchi et al., 2007) , ubiquitination-dead mutant of Akt displayed similar capability to form Akt dimer as WT Akt did ( Figure S4I ), suggesting that Akt ubiquitination does not regulate Akt dimerization.
Skp2 Regulates Glycolysis through Inducing Akt Ubiquitination and Activation
Cancer cells evolve to develop a mechanism that increases glucose uptake and glycolysis to generate higher ATP levels, a phenomenon called Warburg effect (Warburg, 1956) . The Warburg effect is critically regulated by Akt, which is highly activated in human cancers (Elstrom et al., 2004; Manning and Cantley, 2007; Plas and Thompson, 2005; Robey and Hay, 2009 ). As Skp2 orchestrates Akt ubiquitination and activation, it is conceivable that Skp2 may regulate glucose uptake and glycolysis. Indeed, we found that Skp2 knockdown suppressed glucose uptake and glycolysis in breast cancer cells upon EGF or HRG stimulation, as determined by lactate production and glucose incorporation assays , in a manner similar to that of PI3K/Akt inhibition (Figures 4B and 4C and S5D and S5F) . To further investigate whether Skp2 regulates in vivo glycolysis and breast cancer development, we monitored the impact of Skp2 expression on in vivo glucose uptake and subsequent tumor growth in a xenograft model bearing Her2-overexpressing breast tumors. Although in vivo glucose uptake was enriched in control-silenced breast tumors, it was profoundly reduced upon Skp2 knockdown, which correlated with tumor suppression upon Skp2 silencing ( Figures 4D-4G) . Accordingly, Skp2 promotes in vivo glycolysis and breast cancer development.
Intriguingly, introduction of Myr-Akt, a constitutively active form of Akt, rescued the defect in lactate production of Skp2-knockdown cells in the presence of EGF or HRG (Figures 5A and S6A and S6B) , suggesting that Skp2 regulates glycolysis in cancer cells through modulating Akt activation. Because Akt regulates glucose uptake by inducing gene expression and membrane translocation of Glut1 (glucose transporter type 1), a predominant glucose transporter expressed in most cell types (Barthel et al., 1999; Wieman et al., 2007) , we examined whether Glut1 is a downstream target of Skp2 in regulating glycolytic phenotype. As expected, Skp2 deficiency reduced Glut1 transcription and protein expression in breast cancer cells, recapitulating the phenotype driven by Akt inactivation (Figures 5B,   5C , and 5F and S5E-S5G). Importantly, we found that Glut1 protein expression in both membrane fraction and total cell extracts was markedly induced by EGF in control-knockdown cells; however, this induction was impaired in Skp2-deficient cells (Figures 5D and 5E and S6C) . The inhibition of Glut1 protein expression in Skp2-knockdown cancer cells was also rescued by the introduction of Myr-Akt ( Figure 5F ), underscoring that Skp2 regulates Glut1 expression through Akt activation.
To further support our notion that Skp2 regulates glycolysis through Akt ubiquitination, we introduced Akt-Wt, Myr-Akt and Akt-K8R/K14R in Skp2-deficient cells to investigate their effects on glucose metabolism. Notably, although the introduction of Akt-Wt or Myr-Akt rescued the defect in lactate production of Skp2-knockdown cells in the presence of EGF or HRG, Akt-K8R/K14R mutant failed to do so (Figures 5G and S6A and S6B) . These results indicate that Skp2 controls glycolysis in cancer cells through regulating Akt ubiquitination and activation.
Skp2 Loss Attenuates Akt Activity, Glut1 Expression, and Mammary Tumor Development in MMTV-Neu Mice As Skp2 is critical for ErbB receptor signaling, we examined the role of Skp2 loss in Akt activation, Glut1 expression, and tumorigenesis in MMTV-Neu transgenic mice, which develop primary and metastatic breast cancer (Oshima et al., 2004) . KaplanMeier survival analysis revealed that Skp2 deficiency significantly prolonged the survival of MMTV-Neu mice ( Figure 6A) . Notably, Skp2 deficiency markedly delayed breast cancer development and reduced breast tumor volume in MMTV-Neu mice, thereby restricting breast cancer metastasizing to the lungs ( Figures 6B-6E ). Skp2 loss also inhibited in vivo Akt activation and Glut1 expression in MMTV-Neu mice, correlated with the reduced Ki-67 expression of MMTV-Neu mice ( Figure 6F ). Collectively, Skp2 deficiency inhibits Akt activation and Glut1 expression in vitro and in vivo, in turn repressing breast cancer development.
Skp2 Serves as a Marker for Poor Prognosis in Her2-Positive Breast Cancer Patients
Because Skp2 regulates Akt activation and tumorigenesis in MMTV-Neu mouse model, we next investigated whether Skp2 correlates with Akt activation and serves as a marker for poor prognosis in Her2-positive breast cancer patients. For this purpose, we have retrospectively identified 213 consecutively treated breast cancer patients that received modified radical mastectomy with curative intent and without neither pre-nor postoperative adjuvant chemotherapy and/or radiation therapy. Among them, 80 cases were Her2-positve (defined as 3+), whereas 132 were Her2-negative (defined as 0 to 2+). In these 80 cases of Her2-positive breast carcinomas, Skp2 overexpression was significantly correlated with numerous adverse clinicopathological factors, including increments of primary tumor status (pT, p = 0.05), nodal metastasis (pN, p = 0.012), and stage (p = 0.026) (Table S1 ). Skp2 expression also significantly correlated with the upregulation of pAkt (S473) (p < 0.001) ( Figure 7A and Table S1 ). We next asked the question whether Skp2 expression also correlates with both Akt1 and Akt2 phosphorylation in breast tumors. Interestingly, phosphorylation of both Akt isoforms was higher in Skp2-high tumors than that in Skp2-low tumors, and Skp2 expression nicely correlated with Her2 levels in breast tumors ( Figure 7B ). Our results suggest that Skp2 upregulation in Her2-positve breast tumors may contribute to activation of Akt1 and Akt2, thereby promoting breast cancer progression in Her2-positive breast cancer patients.
As Akt-mediated Skp2 S72 phosphorylation stabilizes Skp2 expression and enhances its E3 ligase activity (Gao et al., 2009; Lin et al., 2009) , we asked the question whether this Akt-mediated phosphorylation of Skp2 may serve as a positive feedback loop for Akt ubiquitination. Indeed, we found that the Skp2 S72A mutant defective in Akt-mediated phosphorylation Figure S7 and Tables S1, S2, S3, and S4. reduced its ability to promote Akt ubiquitination compared to WT Skp2 ( Figure S7A ). Moreover, we found that the Skp2-S72A mutant was defective in promoting Akt phosphorylation and activation in breast cancer cells ( Figure S7B) . Interestingly, the level of Skp2 S72 phosphorylation was upregulated and correlated with pAkt levels in multiple breast cancer cell lines (Figure S7C) , suggesting that Skp2 phosphorylation is upregulated in breast cancer cells and correlates with Akt activation. Moreover, Skp2 S72A mutant compromised its ability to promote breast cancer cell migration and invasion compared to that of WT Skp2 (Figures S7D and S7E) , correlated with its defect in promoting Akt ubiquitination and activation ( Figures S7A and  S7B ). Future work would be required to further understand whether Skp2 phosphorylation orchestrates breast cancer metastasis.
In the univariate survival analysis, Skp2 (p = 0.0048 by continuous scoring) and pAkt (S473) (p = 0.0134) overexpression, together with pT status (p < 0.0001), pN status (p = 0.0016), and stage (p < 0.0001) effectively predicted inferior metastasisfree survival (p = 0.0002 by binary cut-offs) ( Figure 7C and Table  S2 ). In the multivariate analysis, although Skp2 overexpression remained prognostically significant for metastasis-free survival in Her2-positive breast cancer patients (p = 0.0343 by continuous scoring in multivariate analysis, p = 0.0048 by continuous scoring in univariate analysis) (Table S2 ), this prognostic effect was not significant in our 132 in-house Her2-negative breast cancers (p = 0.1065 by continuous scoring in univariate analysis and p = 0.0891 by binary cut-offs) ( Figure 7D and Table S3) . Moreover, Skp2 level did not significantly correlate with pAkt (S473) level in Her2-negative breast cancer samples (p = 0.672, Table S4 ). To further strengthen our notion that Skp2 serves as a biomarker for poor prognosis, we have analyzed the correlation between Skp2 and Her2 mRNA levels in NKI dataset (van de Vijver et al., 2002) and found that high Skp2 mRNA level significantly predicted inferior distal metastasis-free survival (p = 0.0018) in Her2 overexpressing breast cancer, but not in Her2 low expressing breast cancer (p = 0.1364) ( Figures  S7F and S7G) . Our results collectively suggest that the status of Skp2 expression can predict survival outcome of Her2-positive breast cancer patients.
Skp2 Deficiency Enhances Herceptin Sensitivity in Her2-Positive Cancer Cells and Tumors
Herceptin is the standard treatment for Her2-positive breast tumors that substantially improves the clinical outcomes of these patients. However, there are still a number of patients that display intrinsic or acquired resistance to this treatment. The discordant Herceptin responses among Her2-positive patients are possibly due to the heterogeneous nature of tumors. As Skp2 deficiency or knockdown inhibits glycolysis in mouse tumor models ( Figures 4D-4F and 6F ), we examined whether Skp2 targeting sensitizes Herceptin response in Her2-positive cancer cells and tumors. Indeed, the Herceptin sensitivity was significantly enhanced in Skp2-silenced cells (Figures 7E and S7H) . In preclinical mouse model, although Herceptin by itself inhibited tumor growth, it did not cause tumor shrinkage (Figure 7F) . Strikingly, Skp2 silencing in conjunction with Herceptin treatment resulted in substantial tumor regression ( Figure 7F ), highlighting that Skp2 is an appealing therapeutic target to combine with Herceptin for anticancer treatment.
To support the notion that Skp2 regulates Herceptin resistance through promoting Akt ubiquitination and activation, we introduced Akt-K8R/K14R, Akt-WT, and Myr-Akt in Skp2-silenced cells to examine their effects on Herceptin sensitivity. Notably, overexpression of WT Akt or Myr-Akt prevented heightened Herceptin sensitivity in Skp2-silecned cells, whereas Akt-K8/K14R overexpression failed to do so ( Figure 7G ), elucidating that Skp2 regulates Herceptin resistance through promoting Akt ubiquitination.
DISCUSSION
Our results reveal several unexpected findings with important clinical implications. We identify that the Skp2 SCF complex is a crucial E3 ligase for promoting Akt ubiquitination and activation, thereby resulting in elevated glycolysis and tumorigenesis in response to ErbB receptor signaling ( Figure 7H ). Importantly, we provide preclinical evidence demonstrating that targeting glycolysis drastically benefits therapeutic outcomes for current anticancer treatments.
Different Growth Factors Utilize Distinct E3 Ligases for Akt Ubiquitination and Activation
Our current and previous findings establish that K63-linked ubiquitination of Akt is a general event triggered by growth factors and cytokines, such as IGF-1, EGF and interleukin-1, and plays a critical role in Akt membrane recruitment and activation. Although TRAF6 is required for IGF-mediated Akt ubiquitination and activation, our current study reveals that Skp2, but not TRAF6, is selectively engaged in Akt ubiquitination and activation driven by activation of ErbB family receptors. Given that other growth factors like PDGF and FGF are known to activate Akt signaling and we also revealed that Skp2 increased association with Akt upon stimulation of PDGF, but not FGF (data not shown), it remains to be determined whether Skp2 is involved in PDGF-mediated Akt ubiquitination and activation.
Skp2 SCF Complex Regulates Nonproteolytic K63-Linked Ubiquitination
Skp2 SCF complex is known to play a critical role in cell cycle regulation and tumorigenesis by promoting ubiquitination and degradation of p27 and p21 (Chan et al., 2010b; Lin et al., 2010; Nakayama and Nakayama, 2006) . We identify that Akt is a Skp2 SCF substrate, whose ubiquitination does not lead to degradation. Thus, Akt is a substrate of Skp2 SCF complex that undergoes K63-linked ubiquitination. As Skp2 and other F-box proteins are long thought to promote ubiquitination and degradation of their substrates, our current study challenges this dogma by identifying Akt as a nonproteolytic substrate for Skp2. In light of this unexpected finding, we speculate that there may be more Skp2 protein substrates undergoing nonproteolytic K63-linked ubiquitination.
Skp2 Regulates Aerobic Glycolysis, the Warburg Effect
Elevated aerobic glycolysis is a hallmark in various tumor origins, as evidenced by the wide application of PET scan in clinical diagnosis for detecting cancer cells with actively glucose uptake (Zhu et al., 2011) . Thus, identifying factors that control cancer cell glycolysis not only can advance current knowledge of how tumor cells seize glucose metabolism to acquire survival advantage, but also provide innovative approaches for cancer therapy. Our present study uncovers an unrecognized function of Skp2 in glucose metabolism. We identify Skp2 as a critical regulator for glycolysis by regulating Akt ubiquitination and activation.
Hypoxia-inducible factor-1a (HIF-1a) can activate transcription of genes encoding Glut1, Hexokinase II, Lactate dehydrogenase A (LDH-A), as well as pyruvate dehydrogenase kinase 1 (PDK1). As such, HIF-1a accumulation stimulates glucose metabolism by increasing both glucose consumption and lactate production as PDK1 inhibits conversion of pyruvate to acetylCoA and suppresses oxidative phosphorylation. Because activation of Akt/mTOR is known to enhance HIF-1a translation (Jiang et al., 2001; Majumder et al., 2004) , it is likely that Skp2 may also upregulate HIF-1a translation and induces HIF-1-dependent glycolysis through the Akt/mTOR pathway.
In addition to the Skp2-Akt axis, we cannot rule out the possibility that Skp2 may also cooperate with other key regulators to participate in glucose metabolism or other metabolic pathways. For instance, Myc overexpression increases transcription of many metabolic enzymes, including glycolytic enzymes (Glut1 and Hexokinase II), LDH-A, and several enzymes required for nucleotide biosynthesis (DeBerardinis et al., 2008; Osthus et al., 2000; Shim et al., 1997) . Because Skp2 cooperates with Myc to activate various Myc target genes involved in cell cycle transition or cell migration (Chan et al., 2010a; Kim et al., 2003; von der Lehr et al., 2003) , it implies that Skp2 may participate in Myc-dependent metabolic processes through inducing the transcription of metabolic target genes. Future study will be needed to explore this possibility.
Skp2 Is a Marker for Poor Survival Outcomes and a Potential Therapeutic Target for Her2-Positive Breast Cancer The PI3K/Akt is one of the most important oncogenic pathways activated downstream of Her2/ErB2 in cancers (Hynes and MacDonald, 2009 ). Our study reveals that Skp2 overexpression correlates with Akt activation and poor survival outcomes in Her2-posivtive breast cancer patients, but not in Her2-negative ones, supporting the in vivo relevance of Skp2 in ErbB family receptor-induced Akt activation and breast cancer progression. Our findings demonstrating the pronounced defect of Skp2 silencing in glucose uptake of Her2-overexpressing tumor suggests that Skp2 targeting is a promising strategy for inhibiting glycolysis and cancer ( Figures 4D-4G ). Because Skp2 also recognizes and promotes degradation of p27 and p21 (Bornstein et al., 2003; Nakayama et al., 2000; Nakayama and Nakayama, 2006) , it is possible that downregulation of p27 or p21 may also contribute to tumor progression or poor survival outcome driven by Skp2 overexpression.
In addition to Her2/Neu overexpression, Skp2 loss also impacts tumorigenesis driven by Pten, pRB, and p19ARF inactivation in various transgenic mouse models (Lin et al., 2010; Wang et al., 2010) . It is possible that Skp2 silencing may globally inhibit glycolysis driven by various oncogenic insults through regulating Akt activation or other mechanisms. Our findings along with these recent reports thereby suggest that targeting glycolysis pathways can be an important therapeutic approach for cancer treatment.
Multiple genetic or epigenetic alterations have been revealed in various cancer types. Therefore, designing a strategy that universally targets fundamental features of cancer cells, such as glycolysis, may serve as a valuable anticancer approach. Several small molecules that pharmacologically inactivate glycolysis have emerged and shown promising anticancer activities as single agent or in combination with other therapeutic modalities (Pelicano et al., 2006; Vander Heiden et al., 2009) . In support of this notion, our discovery reveals that Skp2 silencing as a therapeutic strategy to inactivate glycolysis can sensitize Her2-positive cells/tumors response to Herceptin . As such, our study provides a proofof-principle that targeting glycolysis is a compelling therapeutic strategy as a single or a combinatory therapy for cancer treatment.
EXPERIMENTAL PROCEDURES
Mice, Cell Culture, and Reagents
MMTV-Neu and Skp2
À/À mice were described (Lin et al., 2010; Nakayama et al., 2000; Oshima et al., 2004) . Mouse embryonic fibroblasts (MEFs) from wild-type and Skp2 À/À mice were prepared as previously described (Lin et al., 2004 (Lin et al., , 2010 . All manipulations were performed under IACUC approval protocol. 293T, Cos1, BT-474, and MDA-MB-231 cells were cultured in DMEM containing 10% fetal bovine serum (FBS). (His) 6 -ubiquitin, (His) 6 -ubiquitin-K48R and (His) 6 -ubiquitin-K63R, GST-Akt1, HA-Akt1 constructs was described previously ). Skp2-LRR construct was from W. Tansey. Herceptin was a gift from Dr. M.H. Lee.
In Vivo and In Vitro Ubiquitination Assay
In vivo and in vitro ubiquitination assays were performed as described Yang et al., 2009) . For in vivo ubiquitination assay, 293T cells were transfected with the indicated plasmids for 48 hr and lysed by the denatured buffer (6 M guanidine-HCl, 0.1 M Na 2 HPO 4 /NaH 2 PO 4 , 10 mM imidazole). The cell extracts were then incubated with nickel beads for 3 hr, washed, and subjected to immunoblotting analysis. For in vitro ubiquitination assays, recombinant GST and GST-Akt proteins were purified from the bacterial lysates of BL21 competent cells. Flag-Skp2 SCF complex and Flag-TRAF6 were expressed in 293T cells, immunoprecipitated by anti-Flag antibody, and eluted from Protein A/G beads using Flag peptides according to manufacturers' standard procedures. Purified GST, GST-Akt, Flag-SCF, and Flag-TRAF6 proteins were incubated for 3 hr at 37 C in 20 ml of reaction buffer (20 mM HEPES [pH 7.4], 10 mM MgCl 2 , 1 mM DTT, 59 mM ubiquitin, 50 nM E1, 850 nM of Ubc13/Uev1a, 1 mM ATP, 30 mM creatine phosphate, and 1 U of creatine kinase). After incubation, protein mixtures were diluted in RIPA buffer and the supernatant fluid was precleared with Protein A/G beads for 1 hr, and immunoprecipitated overnight with anti-Flag antibody, after which Protein A/G beads were added for an additional 1 hr. Beads were washed four times with E1A Buffer. Proteins were eluted in SDS-sample buffer and subjected to immunoblotting analysis. All animal experiments were performed under IACUC approval protocol.
Glucose Uptake Assay Cells were seeded in 60 mm plates. Twenty-four hours later, cells were refreshed with serum-starved (0.1% FBS) and glucose-free DMEM. Sixteen hours later, cells treated with or without 10 mM LY294002 were grown in the presence of 50 mM 2-NBDG for 30 min and 60 min, respectively, and glucose uptake was quantified using FACS analysis.
Lactate Production Assay
Cells were plated in 24-well plate and cultured overnight. After pretreated with or without 10 mM LY294002, cells were treated with EGF (50 ng/ml) for 8 hr.
Culture medium was removed from cells and lactate concentration was determined using lactate test strips and Accutrend Lactate analyzer (Accutrend Lactate, Roche). Next, cells were harvested, stained with trypan blue, and viable cell numbers were counted directly under the microscope using hemocytometer. Last, the rate of lactate production were determined (lactate production rate = lactate concentration/cells/time) and normalized with the rate detected in control group. knockdown were seeded in 12-wells in triplicate, 24 hr later, treated with Herceptin (refreshed every 2 days). Six days later, cells were harvested, stained with trypan blue, and viable cells were counted directly under the microscope using hemocytometer.
Immunohistochemistry and Scoring
The procedures of immunohistochemical studies were performed as previously described . In brief, sections were cut onto an adhesive-coated glass slides at 3-mm thickness. For stainings in human samples, the slides were incubated with primary antibodies targeting Her-2 (Thermo Scientific, Clone SP3, 1:100), Skp2 (Invitrogen, clone 2C8D9, 1:100), and pAkt (Ser473) (Cell Signaling, clone D9E, 1:25) . The slides from mouse samples were incubated with primary antibodies for pAkt (Ser473) (Cell Signaling, clone D9E, 1:25), polyclonal, 1:200) , and Glut1 (Abcam, clone SPM498, 1:200), respectively. Primary antibodies were detected using the ChemMate DAKO EnVision kit (DAKO, K5001). The slides were incubated with the secondary antibody for 30 min and developed with 3,3-diaminobenzidine for 5 min. Incubation without the primary antibody was used as a negative control. Immunoexpression was scored by two pathologists (C.F.L and H.Y.H.) using a multiheaded microscope to reach a consensus for each case. The staining was evaluated based on a combination of both the percentage and intensity of positively stained tumor cells to generate an H-score, which was calculated using the following equation: H-score = SPi (i + 1), where i is the intensity of the stained tumor cells (0 to 4 +), and Pi is the percentage of stained tumor cells for each intensity.
Statistical Analysis
Statistical analyses were performed using the SPSS 14 software package. For human breast samples, the Mann-Whitney U test was used to assess the differential expression level of Skp2 and pAkt (S473) expression in relation to
Her-2 expression status. The Spearman's rank correlation coefficient was used to clarify the association between Skp2 expression to clinicopathological variables and pAkt (Ser473) expression levels. The endpoint analyzed was distal metastasis-free survival, calculated from the starting date of surgery to the date of event. The median period of follow-up was 103 months (range, 6-143) . Survival analysis was performed using the Cox proportional hazards model. Survival curves were plotted using the Kaplan-Meier method, and log-rank tests were performed to evaluate prognostic differences between groups for categorical variables. For mouse samples, the expression levels of pAkt, Ki-67, and Glut1 between various groups were assessed by using Mann-Whitney U test. For all analyses, two-sided tests of significance were used with p = <0.05 considered significant.
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